Analys

NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead

2023-02-17• Analys, Research

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two...

Read More →

AGTIRA: Looking to maintain momentum into 2023

2023-02-15• Analys, Research

Agtira closed its books for 2022 reaching record high sales of 25.5 MSEK, an 80% increase compared to 2021. While the growth was strong, we...

Read More →

CRUNCHFISH: Video interview with CEO Joachim Samuelsson on ”the paradigm shift in payments” + feedback from India: ”Scale it up”

2023-02-01• Analys, Research

https://youtu.be/kmv2PDFQQdM Read the press release from Crunchfish here READ EMERGERS’ EQUITY RESEARCH ON CRUNCHFISH HERE CRUNCHFISH:...

Read More →

QLUCORE: Interview with CEO Carl-Johan Ivarsson about the important issues in 2023 and the revenue target of SEK 300 million in 2027

2023-02-01• Analys, Research

READ EMERGERS’ EQUITY RESEARCH ON QLUCORE HERE QLUCORE: At the vanguard of both oncology research and life science M&A With a strong...

Read More →

CRUNCHFISH: The most interesting fintech rollout since iZettle

2023-01-24• Analys, Research

With the rise of digital cash, the shift to online has created a gap for users with poor or no connectivity, forcing emerging...

Read More →

BONZUN: Evidence-based DTx scaling up to combat stress and infertility

2023-01-24• Analys, Research

We re-initiate coverage on digital therapeutics (DTx) company Bonzun that offers evidence-based patient support for fertility treatments...

Read More →

FOM TECHNOLOGIES: Ready for takeoff

2023-01-24• Analys, Research

RESEARCH COLLABORATION WITH ENLIGHT RESEARCH FOM is active in the small but fast growing market for coating solutions to the...

Read More →

QLUCORE: At the vanguard of both oncology research and life science M&A

2023-01-20• Analys, Research

With a strong trend in oncology and life science R&D in favour of precision medicine, data analysis and AI, Qlucore is uniquely...

Read More →

NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing

2022-12-23• Analys, Research

The combination of an exclusive evaluation agreement and directed share issue to Novo Nordisk, global leader in diabetes treatment,...

Read More →

KEBNI: Massive order intake for Saab lowers risk in IMU ramp-up markedly

2022-12-19• Analys, Research

In the first half of December, KebNi’s single most important customer, defence company Saab has received two orders for its handheld...

Read More →

NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead

AGTIRA: Looking to maintain momentum into 2023

CRUNCHFISH: Video interview with CEO Joachim Samuelsson on ”the paradigm shift in payments” + feedback from India: ”Scale it up”

QLUCORE: Interview with CEO Carl-Johan Ivarsson about the important issues in 2023 and the revenue target of SEK 300 million in 2027

CRUNCHFISH: The most interesting fintech rollout since iZettle

BONZUN: Evidence-based DTx scaling up to combat stress and infertility

FOM TECHNOLOGIES: Ready for takeoff

QLUCORE: At the vanguard of both oncology research and life science M&A

NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing

KEBNI: Massive order intake for Saab lowers risk in IMU ramp-up markedly

Widmark Research

CONTACT